Patients with diabetes are at higher risk of cardiovascular diseases and cognitive
impairment. SGLT2 inhibitors (Empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin …

The known genetic architecture of blood pressure now comprises> 30 genes, with rare
variants resulting in monogenic forms of hypertension or hypotension and> 1,477 common …

Alzheimer's disease (AD) is the sixth leading cause of death in the USA today; therefore, it is
imperative that public health initiatives and clinical strategies are developed to prevent and …

Neurons need a continuous supply of glucose, the major source of energy for mammalian
brain metabolism. The central nervous system is protected by three main physiological cell …

Alzheimer's disease (AD) is the most prevalent form of dementia, particularly in old age
subjects. Hyperinsulinemia and insulin resistance, which are known as pathophysiological …

Objective Diabetes is a risk factor for dementia, but whether antidiabetic medication
decreases the risk is unclear. We examined the association between antidiabetic medication …

Background Preclinical studies have suggested potential beneficial effects of newer glucose‐
lowering drugs (GLDs) including dipeptidyl peptidase (DPP)‐4 inhibitors, glucagon‐like …

Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are oral anti-hyperglycemic agents
approved for the treatment of type 2 diabetes mellitus. Some reports suggest their presence …

Background The association of the use of sodium-glucose cotransporter 2 (SGLT2) inhibitor
and incident dementia remains unclear. This study aimed to evaluate the risk of incident …

Diabetes and obesity are growing problems worldwide and are associated with a range of
acute and chronic complications, including acute myocardial infarction (AMI) and stroke …